Gilead Sciences Inc.’s hepatitis C cure set off a firestorm of criticism over high drug prices in 2014 that hasn’t let up since. Now an executive says the company can’t cut the product’s price because middlemen who manage drug benefits would refuse to cover it.
Category: Foster City, CA
Gilead’s Biggest Blockbusters Are Fading Fast, Biotech Warns
Gilead Sciences Inc.’s massive hepatitis C franchise is fading, the company warned Tuesday, projecting that sales this year could be just two-thirds of what investors had been expecting. Revenue from the company’s drugs for the viral infection will be $7.5 billion to $9 billion in 2017, Gilead said in a statement.